Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. ACAD Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

ACADIA Pharmaceuticals (ACAD)

Market Price (9/18/2025): $24.195 | Market Cap: $4.1 Bil
Sector: Health Care | Industry: Pharmaceuticals

ACADIA Pharmaceuticals (ACAD)

Market Price (9/18/2025): $24.195
Market Cap: $4.1 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.5%		 Weak multi-year price returns
2Y Excs Rtn is -54%, 3Y Excs Rtn is -25%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 45x
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -17%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%		  
3 Low stock price volatility
Vol 12M is 49%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.5%
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -17%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%
3 Low stock price volatility
Vol 12M is 49%
4 Weak multi-year price returns
2Y Excs Rtn is -54%, 3Y Excs Rtn is -25%
5 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 45x

Market Valuation

 9/18/252024202320222021
Share Price CYE$24.20$18.35$31.31$15.92$23.34
Market Cap CYE ($ Bil)4.13.15.22.63.8
Total Debt ($ Bil)0.10.10.10.10.1
Total Cash ($ Bil)0.80.80.40.40.5
Enterprise Value ($ Bil)3.43.25.32.73.9
Valuation Ratios     
P/S TTM4.03.27.15.07.7
P/EBIT TTM45.036.1-69.9-11.5-22.0
P/E TTM18.313.4-83.7-11.9-22.3
Sector Ratios     
P/S TTM (Sector)3.83.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/18/2520242023
Share Price CYE$24.20$18.35$31.31
Market Cap CYE ($ Bil)4.13.15.2
Total Debt ($ Bil)0.10.10.1
Total Cash ($ Bil)0.80.80.4
Enterprise Value ($ Bil)3.43.25.3
Valuation Ratios   
P/S TTM4.03.27.1
P/EBIT TTM45.036.1-69.9
P/E TTM18.313.4-83.7
Sector Ratios   
P/S TTM (Sector)3.83.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
ACAD Return25%-56%-32%97%-41%32%-45%
Peers Return13%13%4%2%3%14%58%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ACT, ARWR, OGN, LLY, JNJ. See ACAD Returns vs. Peers.
[3] 2025 data is for the year up to 9/17/2025 (YTD)

Better Bets than ACADIA Pharmaceuticals (ACAD)

 ACADBetter Performance than ACAD
MetricValueIndustry (Pharmaceuticals)
Rev Chg LTM14.4%LLY (36.8%), CORT (25.7%), KNSA (56.2%), ALVO (82.6%), ANIP (38.7%)
Rev Chg 3Y Avg27.9%KNSA (96.3%), ALVO (150.9%), ANIP (44.2%), BCRX (40.4%), HROW (39.8%)
Op Mgn LTM8.9%LLY (43.0%), JNJ (24.5%), MRK (31.2%), PFE (26.1%), BMY (16.5%)
CFO/Rev LTM18.4%LLY (20.5%), JNJ (25.4%), MRK (29.1%), PFE (23.8%), BMY (30.0%)
FCF/Rev LTM8.7%JNJ (18.1%), MRK (23.1%), PFE (19.5%), BMY (27.5%), ZTS (23.6%)
Total Yield5.5%JNJ (8.1%), MRK (12.0%), PFE (13.2%), BMY (11.0%), ALKS (7.6%)
 ACADBetter Performance than ACAD
MetricValueAll Other Sectors
Rev Chg LTM14.4%NVDA (71.6%), MSFT (14.9%), META (19.4%), AVGO (28.0%), NFLX (14.8%)
Rev Chg 3Y Avg27.9%NVDA (92.0%), ANET (32.1%), MELI (39.8%), CRWD (33.5%), DASH (28.4%)
Op Mgn LTM8.9%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM18.4%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), META (56.4%)
FCF/Rev LTM8.7%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), META (30.7%)
Total Yield5.5%BRK-B (5.9%), JPM (6.5%), XOM (9.7%), HD (5.7%), BAC (7.1%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1ACADIA Pharmaceuticals Earnings Notes  
2ACAD Dip Buy Analysis  
3ACADIA Pharmaceuticals Market PriceMarket Price 
4ACADIA Pharmaceuticals (ACAD) Operating Cash Flow ComparisonFinancials 
5ACADIA Pharmaceuticals (ACAD) Net Income ComparisonFinancials 
6ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $172 Bil), more valuable than Meta PlatformsNotification 
7ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $197 Bil), more valuable than Meta PlatformsNotification 
8ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $197 Bil), more valuable than Meta PlatformsNotification 
9ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $177 Bil), more valuable than Meta PlatformsNotification 
10ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $180 Bil), more valuable than Amazon.comNotification 
11ARTICLES  
12These Healthcare Stocks Took A Beating Through Covid. Will They Outperform In 2022? February 23rd, 2022
13Will Acadia Pharmaceuticals Stock See Higher Levels After A Large 26% Rally In A Month? January 5th, 2022
14These Healthcare Stocks Lagged This Year, But Might Offer Deep Value December 16th, 2021
15Neurocrine, ACADIA: Fast Growing Health Care Stocks That Are Underperforming October 25th, 2021
16How Does Acadia Stock Performance In The Current Crisis Compare With That In 2008? September 7th, 2021
Title
0DASHBOARDS
1These Healthcare Stocks Took A Beating Through Covid. Will They Outperform In 2022?
2Will Acadia Pharmaceuticals Stock See Higher Levels After A Large 26% Rally In A Month?
3These Healthcare Stocks Lagged This Year, But Might Offer Deep Value
4Neurocrine, ACADIA: Fast Growing Health Care Stocks That Are Underperforming
5How Does Acadia Stock Performance In The Current Crisis Compare With That In 2008?
6ARTICLES
7ACADIA Pharmaceuticals Earnings Notes
8ACAD Dip Buy Analysis
9ACADIA Pharmaceuticals Market Price
10ACADIA Pharmaceuticals (ACAD) Operating Cash Flow Comparison
11ACADIA Pharmaceuticals (ACAD) Net Income Comparison
12ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $172 Bil), more valuable than Meta Platforms
13ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $197 Bil), more valuable than Meta Platforms
14ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $197 Bil), more valuable than Meta Platforms
15ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $177 Bil), more valuable than Meta Platforms
16ACADIA Pharmaceuticals (ACAD) worth $1.9 Tril (up $180 Bil), more valuable than Amazon.com

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11931.7%11931.7%
2GIBOGIBO10714.0% 
3LNZALanzaTech Global8455.2%-86.3%
4GTIGraphjet Technology3998.4%-93.1%
5GWAVGreenwave Technology Solutions3582.8%-91.4%
6QMMMQMMM3409.6%8153.1%
7ECDAECD Automotive Design2715.2%307.9%
8OESXOrion Energy Systems1373.7%14.2%
9OPOceanPal1266.5%-95.6%
10BCTXBriaCell Therapeutics1032.4%-89.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-94.5%-96.0%
2STFSStar Fashion Culture-92.3%-97.9%
3ELPWElong Power-91.1%-76.9%
4NXTTNext Technology-90.1%-95.4%
5EPIXESSA Pharma-89.4%-8.9%
6NAKAKindly MD-88.1% 
7BINIBollinger Innovations-87.6%-100.0%
8JEM707 Cayman-87.4%-98.2%
9YAASYouxin Technology-83.3%-98.4%
10NEONNeonode-82.5%-51.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1ECDAECD Automotive Design3347.2%307.9%
2BDSXBiodesix1090.6%-79.7%
3CLSDClearside Biomedical987.7%-74.7%
4ATHAAthira Pharma892.1%544.3%
5SDOTSadot690.6%-79.9%
6ATCHAtlasClear684.9%-83.1%
7HSDTHelius Medical Technologies232.1%-95.5%
8CHEKCheck-Cap222.2%134.4%
9APLMApollomics197.8%89.1%
10SPRCSciSparc147.0%1141.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1CURXCuranex Pharmaceuticals-80.5%148.4%
2ATYRaTyr Pharma-80.4%-71.7%
3NAKAKindly MD-70.2% 
4BNGOBionano Genomics-64.0%-89.8%
5XAGELongevity Health-57.6%-86.1%
6FAASDigiAsia-55.4%-88.0%
7ASSTStrive-54.5%650.3%
8VCIGVCI Global-51.0%-98.9%
9REXREX American Resources-50.7%44.3%
10RBNERobin Energy-42.6% 

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for ACADIA Pharmaceuticals

Financials

ACADACTARWROGNLLYJNJMedian
NameACADIA P.Enact Arrowhea.Organon Eli LillyJohnson . 
Mkt Price24.2037.7429.1310.45760.13177.2033.44
Mkt Cap4.15.74.12.7682.5426.44.9
Rev LTM1,0191,2265736,28153,25890,6273,753
Op Inc LTM90--1081,33722,88222,2281,337
FCF LTM88701-18482-5016,397285
FCF 3Y Avg45641-298530-15616,926287
CFO LTM1887012282610,93823,028763
CFO 3Y Avg78641-1758727,23022,248757

Growth & Margins

ACADACTARWROGNLLYJNJMedian
NameACADIA P.Enact Arrowhea.Organon Eli LillyJohnson . 
Rev Chg LTM14.4%3.4%2,816.2%-1.0%36.8%4.7%9.5%
Rev Chg 3Y Avg27.9%3.7%908.8%-0.4%23.4%4.0%13.7%
Rev Chg Q9.3%1.9%--0.8%37.6%5.8%5.8%
QoQ Delta Rev Chg LTM2.3%0.5%5.1%-0.2%8.7%1.5%1.9%
Op Mgn LTM8.9%--18.8%21.3%43.0%24.5%21.3%
Op Mgn 3Y Avg-3.9%--958.1%22.2%35.6%26.3%22.2%
QoQ Delta Op Mgn LTM-0.0%-2.9%-0.9%1.8%-0.2%-0.0%
CFO/Rev LTM18.4%57.1%3.8%13.2%20.5%25.4%19.5%
CFO/Rev 3Y Avg7.1%54.5%-620.8%13.9%17.8%25.7%15.8%
FCF/Rev LTM8.7%57.1%-3.1%7.7%-0.1%18.1%8.2%
FCF/Rev 3Y Avg3.8%54.5%-949.2%8.4%0.5%19.6%6.1%

Valuation

ACADACTARWROGNLLYJNJMedian
NameACADIA P.Enact Arrowhea.Organon Eli LillyJohnson . 
Mkt Cap4.15.74.12.7682.5426.44.9
P/S4.04.67.10.412.84.74.7
P/EBIT45.06.2-54.02.338.415.110.7
P/E18.38.4-27.33.949.518.813.3
P/CFO21.68.1185.43.362.418.520.1
Total Yield5.5%14.0%-3.7%34.2%2.8%8.1%6.8%
Dividend Yield0.0%2.1%0.0%8.4%0.7%2.8%1.4%
FCF Yield 3Y Avg1.5%13.4%-8.8%13.3%0.1%4.5%3.0%
D/E0.00.10.13.30.10.10.1
Net D/E-0.2-0.3-0.13.10.10.1-0.0

Returns

ACADACTARWROGNLLYJNJMedian
NameACADIA P.Enact Arrowhea.Organon Eli LillyJohnson . 
1M Rtn-3.4%1.2%46.3%12.6%8.9%1.3%5.1%
3M Rtn5.4%5.8%86.5%6.0%-3.0%18.4%5.9%
6M Rtn40.0%12.5%88.3%-33.5%-8.8%10.5%11.5%
12M Rtn48.8%6.2%45.6%-47.1%-15.5%9.5%7.8%
3Y Rtn34.3%87.5%-15.8%-56.8%152.3%15.8%25.1%
1M Excs Rtn-5.8%-1.1%44.0%10.3%6.5%-1.1%2.7%
3M Excs Rtn-4.2%-2.0%77.6%-4.0%-14.0%6.8%-3.0%
6M Excs Rtn22.5%-3.8%75.4%-50.7%-24.7%-7.9%-5.9%
12M Excs Rtn31.0%-10.4%18.2%-64.2%-34.4%-6.8%-8.6%
3Y Excs Rtn-25.5%10.2%-87.0%-119.0%86.7%-43.4%-34.4%

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/7/20255/8/20252/27/202511/7/20248/7/20245/9/20242/28/202411/3/20238/3/20235/8/20232/28/202311/3/2022
Key Financials Quarterly            
Total Revenue265244260250242206231212165118136131
Ebitda35221234332137-565-53-46-30
Operating Income3219732301535-583-54-46-31
Net Income271914433331746-651-43-42-27
EPS0.160.110.860.200.200.100.28-0.400.01-0.27-0.26-0.17
Key Financials TTM            
Total Revenue TTM1,019996958929891814726632551520517512
Ebitda TTM104102100125346-68-150-124-162-222-220
Operating Income TTM90888411223-5-73-154-127-164-224-222
Net Income TTM22222922612931-2-61-149-111-146-216-217
Growth Rates Quarterly            
Total Revenue Growth9.3%18.7%12.4%18.3%46.4%73.8%69.3%62.0%22.8%2.6%4.4%-0.7%
EBITDA Growth7.0%7.2%-66.6%161.0%587.2%139.0%180.3%-84.6%114.5%52.7%-3.3%-112.1%
Operating Income Growth6.4%26.8%-80.0%154.8%902.2%128.4%175.9%-87.2%109.0%52.6%-3.1%-101.7%
Net Income Growth-20.1%14.7%213.9%150.3%2897.2%138.5%209.8%-139.8%103.3%61.9%3.2%-88.0%
Margins Quarterly            
EBITDA Margin13.3%9.1%4.7%13.7%13.6%10.1%15.8%-26.5%2.9%-44.9%-33.4%-23.2%
Operating Income Margin12.2%7.9%2.7%12.6%12.6%7.4%15.1%-27.3%1.8%-45.2%-33.7%-23.6%
Net Income Margin10.1%7.8%55.4%13.1%13.8%8.0%19.8%-30.8%0.7%-36.3%-30.6%-20.8%
Cash & Debt            
Total Cash762682756565501471439346375403417437
Total Debt565652495860575759616263
Net Debt / (Cash)-706-626-704-516-443-411-382-289-317-342-355-374
Cash Flows Quarterly            
FCF from Operations64204063252985-598-18-24-1
Cash Flows TTM            
FCF from Operations TTM188149158203816417-93-34-56-114-113
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC3.8%2.3%1.1%4.4%4.5%1.9%5.6%-9.1%0.1%-8.4%-7.6%-5.2%
Return on Invested Capital (ROIC) TTM            
ROIC TTM3.3%3.3%3.3%4.4%0.6%-0.2%-3.0%-6.1%-5.1%-6.7%-9.3%-9.3%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
NUPLAZID549517484  
DAYBUE17700  
Product sales, net   442339
Total726517484442339


Price Behavior

ACAD Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta1.421.580.970.820.871.03
Up Beta2.582.121.570.590.680.96
Down Beta1.621.420.550.910.881.07
Up Capture142%212%118%130%136%112%
Bmk +ve Days10223571142415
Stock +ve Days10233159119350
Down Capture23%37%36%89%92%101%
Bmk -ve Days11192754106334
Stock -ve Days11173064124393

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity9,278,091
Short Interest: % Change Since 8152025-7.1%
Average Daily Volume1,895,249
Days-to-Cover Short Interest4.90
Basic Shares Quantity167,827,000
Short % of Basic Shares5.5%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/6/20252.5%5.6%6.1%
5/7/202514.3%15.9%48.4%
2/26/20251.8%-4.8%-9.5%
11/6/20248.9%11.4%9.4%
8/6/2024-19.5%-16.6%-14.0%
5/8/2024-11.2%-11.7%-13.1%
2/27/2024-9.9%-9.7%-31.0%
11/2/20234.7%-4.3%-0.6%
...
SUMMARY STATS   
# Positive1058
# Negative121714
Median Positive3.7%11.4%9.9%
Median Negative-5.1%-4.8%-10.0%
Max Positive14.3%15.9%48.4%
Max Negative-19.5%-16.6%-46.6%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025807202510-Q 6/30/2025
3312025508202510-Q 3/31/2025
12312024227202510-K 12/31/2024
93020241107202410-Q 9/30/2024
6302024807202410-Q 6/30/2024
3312024509202410-Q 3/31/2024
12312023228202410-K 12/31/2023
93020231103202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023508202310-Q 3/31/2023
12312022228202310-K 12/31/2022
93020221103202210-Q 9/30/2022
6302022809202210-Q 6/30/2022
3312022505202210-Q 3/31/2022
12312021301202210-K 12/31/2021
93020211109202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER8192025Sell25.1822,000554,0241,010,590Form
1Brege Laura6052025Sell21.7814,446314,634328,769Form
2Kihara JamesPRINCIPAL ACCOUNTING OFFICER5192025Sell25.002,00050,000559,875Form
3Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER5192025Sell25.002,00050,0001,553,250Form
4GAROFALO ELIZABETH A.3062025Sell18.234,91989,673320,757Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.